Excuse my ignorance but I thought most if not majority of Bio Tech deals get done at PH2 after safety and efficacy shown in approved trials? I know going for Dmoad makes it worth much more but if it means the end of the company becomes a bit nonsensical, if it means more dilution to get the diamonds so be it, problem as I see it waited too long and got deviated to chase a lesser dream that probably not going to eventuate.
Hopefully all not lost here and Scott knows CPR.
Ann: PAR Appoints Business Development Consultant, page-196
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.005(2.08%) |
Mkt cap ! $85.73M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $132.4K | 552.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 93605 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 5156 | 2 |
View Market Depth
| Last trade - 13.52pm 14/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |